Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...

Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the past ...

Sanofi is reorganising its business units from seven to five in a bid to streamline its operations and ensure the success of its ambitious product launch plans. The revamp is the first major ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...

Sanofi’s new products like novel recombinant factor VIII therapy, Altuviiio, respiratory syncytial virus (RSV) antibody, Beyfortus (in partnership with AstraZeneca [AZN]), Pompe disease therapy ...